Japan’s Takara Bio To Market Campylobacter Test
This article was originally published in PharmAsia News
Executive Summary
Takara Bio announced May 20 it will market a campylobacter test kit using polymerase chain reaction method. Takara Bio obtained the technology from Fuso Pharmaceutical and Osaka Prefecture University, who jointly developed the technology. According to the company, campylobacter-caused food poisonings have been increasing recently. The test kit is able to quickly test and specifically identify C. jejuni, which is the causing factor, from C. Coli and C. fetus, the other two kinds of campylobacter. Currently, it takes one week to test and identify, by using the PCR method, the test kit takes as little as three hours. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.